Goldman Sachs Downgrades Zymergen to Neutral, Lowers Price Target to $12
Goldman Sachs analyst Matthew Sykes downgrades Zymergen (NASDAQ:ZY) from Buy to Neutral and lowers the price target from $55 to $12.
HSBC Downgrades Zymergen to Reduce, Announces $8 Price Target
HSBC analyst Sriharsha Pappu downgrades Zymergen (NASDAQ:ZY) from Hold to Reduce and announces $8 price target.
JP Morgan Downgrades Zymergen to Neutral, Announces $12 Price Target
JP Morgan analyst Tycho Peterson downgrades Zymergen (NASDAQ:ZY) from Overweight to Neutral and announces $12 price target.
William Blair Downgrades Zymergen to Market Perform
William Blair analyst Matt Larew downgrades Zymergen (NASDAQ:ZY) from Outperform to Market Perform.
Why Zymergen Stock Is Crashing Today
Zymergen Inc (NASDAQ: ZY) shares continued to plummet in the pre-market trading on Tuesday.
14 Stocks Moving In Tuesday’s After-Hours Session
RingCentral (NYSE: RNG) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and issued Q3 and FY21 EPS and sales guidance above estimates.
Zymergen Says It ‘no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.’
ay Flatley, Chairman of the Board, Appointed Acting CEO; Josh Hoffman to Step Down
Conference Call to be Held at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Today
EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE
Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.